Loading...
XNAS
PHH
Market cap17mUSD
Oct 03, Last price  
11.00USD
Name

Park Ha Biological Technology Co Ltd

Chart & Performance

D1W1MN
XNAS:PHH chart
P/E
P/S
EPS
0.02
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
2m
-3.13%
01,795,000,0001,703,000,0002,332,000,0002,093,000,0002,440,000,000369,000,0002,695,000,0002,762,000,0002,214,000,0002,743,000,0002,842,000,000639,000,000790,000,000622,000,000456,000,000931,0361,919,3892,459,0002,382,000
Net income
479k
-43.83%
98,000,000284,000,000182,000,00072,000,000-16,000,000-12,000,000-254,000,000153,000,00048,000,000-127,000,00034,000,000135,000,000-185,000,000-131,000,000-193,000,000-194,000,000-485,000191,298852,042478,561
CFO
960k
+659.04%
1,588,000,0003,842,000,0002,509,000,000915,000,000748,000,0002,663,000,0001,893,000,0001,283,000,000-1,680,000,0002,786,000,0002,057,000,0002,709,000,000-11,000,000121,000,00073,000,000303,000,000-497,8581,442,306126,537960,470

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Park Ha Biological Technology Co., Ltd., an investment holding firm, is primarily engaged in the creation and development of skincare products within the People's Republic of China. The company's operations are divided into two core areas: direct product sales and a franchise service model. Under its own 'Park Ha' brand, the company offers a comprehensive selection of skincare solutions. These products cater to a spectrum of dermatological needs, ranging from fundamental physical skin protection and exfoliation to repairing the sebum film, achieving surface microecological balance, and providing anti-aging treatments. Park Ha Biological Technology distributes its merchandise to consumers through both its company-owned retail outlets and an extensive network of franchised partners. Established in 2016, the firm's main office is situated in Wuxi, PRC. It operates as a subsidiary of Xiaoqiu Holding Ltd.
IPO date
Dec 27, 2024
Employees
Domiciled in
CN
Incorporated in
KY

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑102023‑102022‑102021‑102017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT